RESUMO
Pneumococcal vaccination is recommended as a quality indicator for management of children with systemic lupus erythematosus. Literature on the immunogenicity of pneumococcal vaccines (PCVs) in children is scant. We sought to prospectively evaluate via an observational study, the immunogenicity to sequential children with lupus. Out of a cohort of 26 patients, approximately 65% achieved > 70% vaccinated serotype antibody levels of > 1.3 mcg/dL following PCV13, and of 22 patients followed through PPSV23 vaccination, 59% achieved the same. Patients with rituximab exposure in the 6 months prior to a vaccination were more likely to not achieve protective serotype levels ( p < 0.01 for PCV13, trend p = 0.07 for PPSV23). Three of 22 patients with no apparent risk factors did not achieve protective serotype levels. Non-responders to PCV13 generally did not respond to PPSV23. Retrospective healthy controls achieved 100% protective levels in response to PPSV23 vaccination, with 95% of serotypes being > 1.3 mcg/dL. Thus, sequential 13- and 23-valent pneumococcal vaccines achieve protective status for approximately two thirds of pediatric lupus patients in our population. Lack of response to vaccine may be secondary to induced or inherent functional impairments in the patient.
Assuntos
Imunogenicidade da Vacina , Lúpus Eritematoso Sistêmico/imunologia , Infecções Pneumocócicas/prevenção & controle , Vacinas Pneumocócicas/imunologia , Adolescente , Criança , Feminino , Humanos , Masculino , Estudos Prospectivos , SorogrupoRESUMO
The gp41 subunit of the human immunodeficiency virus type 1 envelope glycoprotein mediates fusion of the cellular and viral membranes. The gp41 ectodomain is a trimer of alpha-helical hairpins, where N-terminal helices form a parallel three-stranded coiled-coil core and C-terminal helices pack around the core. A deep hydrophobic pocket on the N-terminal core represents an attractive target for antiviral therapeutics. We have employed a soluble derivative of the gp41 core ectodomain and small cyclic disulfide D-peptide inhibitors to define the stoichiometry, affinity, and thermodynamics of ligand binding to this pocket using isothermal titration calorimetry. These inhibitors bind with micromolar affinity to the pocket with the expected stoichiometry of three peptides per gp41 core trimer. There are no cooperative interactions among the three binding sites. Linear eight- or nine-residue D-peptides derived from the pocket-binding domain of the cyclic molecules also bind specifically. A negative heat capacity change is observed and is consistent with burial of hydrophobic surface upon binding. Contrary to expectations for a reaction dominated by the classical hydrophobic effect, peptide binding is enthalpically driven and is opposed by an unfavorable negative entropy change. The calorimetry data support models whereby dominant negative inhibitors bind to a transiently exposed surface on the prefusion intermediate state of gp41 and disrupt subsequent resolution to the fusion-active six-stranded hairpin conformation.
Assuntos
Fármacos Anti-HIV/metabolismo , Proteína gp41 do Envelope de HIV/metabolismo , HIV-1/metabolismo , Peptídeos Cíclicos/metabolismo , Sequência de Aminoácidos , Fármacos Anti-HIV/síntese química , Ligação Competitiva , Calorimetria , Temperatura Alta , Humanos , Ligantes , Dados de Sequência Molecular , Peptídeos Cíclicos/síntese química , Ligação Proteica , Conformação Proteica , Soluções , Termodinâmica , UltracentrifugaçãoRESUMO
HU, a nonspecific histone-like DNA binding protein, participates in a number of genomic events as an accessory protein and forms multiple complexes with DNA. The HU-DNA binding interaction was characterized by fluorescence, generated with the guanosine analogue 3-methyl-8-(2-deoxy-beta-D-ribofuranosyl)isoxanthopterin (3-MI) directly incorporated into DNA duplexes. The stoichiometry and equilibrium binding constants of complexes formed between HU and 13 and 34 bp DNA duplexes were determined using fluorescence anisotropy and analytical ultracentrifugation. These measurements reveal that three HU molecules bind to the 34 bp duplexes, while two HU molecules bind to the 13 bp duplex. The data are well described by an independent binding site model, and the association constants for the first binding event for both duplexes are similar (approximately 1 x 10(6) M(-1)), indicating that HU binding affinity is independent of duplex length. Further analysis of the binding curves in terms of a nonspecific binding model is indicative that HU binding to DNA exhibits little to no cooperativity. The fluorescence intensity also increases upon HU binding, consistent with decreased base stacking and increased solvent exposure of the 3-MI fluorescence probe. These results are suggestive of a local bending or unwinding of the DNA. On the basis of these results we propose a model in which bending of DNA accompanies HU binding. Up to five complex bands are observed in gel mobility shift assays of HU binding to the 34 bp duplexes. We suggest that protein-induced bending of the DNA leads to the observation of complexes in the gel, which have the same molecular weight but different relative mobilities.
Assuntos
Proteínas de Bactérias/química , Proteínas de Ligação a DNA/química , Conformação de Ácido Nucleico , Sítios de Ligação , Desoxiguanosina/análogos & derivados , Desoxiguanosina/química , Dimerização , Eletroforese em Gel de Poliacrilamida , Escherichia coli/química , Polarização de Fluorescência , Corantes Fluorescentes/química , Substâncias Macromoleculares , Oligonucleotídeos/química , Ligação Proteica , Espectrometria de Fluorescência , Ultracentrifugação , Xantopterina/análogos & derivados , Xantopterina/químicaRESUMO
It is generally accepted that cytokinin oxidases, which oxidatively remove cytokinin side chains to produce adenine and the corresponding isopentenyl aldehyde, play a major role in regulating cytokinin levels in planta. Partially purified fractions of cytokinin oxidase from various species have been studied for many years, but have yet to clearly reveal the properties of the enzyme or to define its biological significance. Details of the genomic organization of the recently isolated maize (Zea mays) cytokinin oxidase gene (ckx1) and some of its Arabidopsis homologs are now presented. Expression of an intronless ckx1 in Pichia pastoris allowed production of large amounts of recombinant cytokinin oxidase and facilitated detailed kinetic and cofactor analysis and comparison with the native enzyme. The enzyme is a flavoprotein containing covalently bound flavin adenine dinucleotide, but no detectable heavy metals. Expression of the oxidase in maize tissues is described.
Assuntos
Oxirredutases/genética , Oxirredutases/metabolismo , Zea mays/enzimologia , Arabidopsis/enzimologia , DNA Complementar/genética , Genes de Plantas , Cinética , Oxirredutases/química , Reguladores de Crescimento de Plantas/farmacologia , RNA Mensageiro/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Zea mays/genéticaRESUMO
Diketo acids such as L-731,988 are potent inhibitors of HIV-1 integrase that inhibit integration and viral replication in cells. These compounds exhibit the unique ability to inhibit the strand transfer activity of integrase in the absence of an effect on 3' end processing. To understand the reasons for this distinct inhibitory profile, we developed a scintillation proximity assay that permits analysis of radiolabeled inhibitor binding and integrase function. High-affinity binding of L-731,988 is shown to require the assembly of a specific complex on the HIV-1 long terminal repeat. The interaction of L-731,988 with the complex and the efficacy of L-731, 988 in strand transfer can be abrogated by the interaction with target substrates, suggesting competition between the inhibitor and the target DNA. The L-731,988 binding site and that of the target substrate are thus distinct from that of the donor substrate and are defined by a conformation of integrase that is only adopted after assembly with the viral end. These results elucidate the basis for diketo acid inhibition of strand transfer and have implications for integrase-directed HIV-1 drug discovery efforts.
Assuntos
Acetoacetatos/farmacologia , DNA Viral/metabolismo , Inibidores de Integrase de HIV/farmacologia , Integrase de HIV/química , HIV-1/enzimologia , Pirróis/farmacologia , Sequência de Bases , Catálise , Primers do DNA , Epitopos/metabolismo , Integrase de HIV/metabolismo , HIV-1/genética , Especificidade por SubstratoRESUMO
The major purposes of this study were to determine the maximally tolerated dose (MTD), dose-limiting toxicity (DLT), toxicity profile, and antitumor activity of gemcitabine (GEM) (Gemzar) and 5-fluorouracil (5-FU) combination therapy when administered to patients with advanced solid tumors. GEM was administered intravenously over 30 minutes on days 1, 8, and 15, and 5-FU was administered as a continuous intravenous infusion from day 1 through day 15 of each 28-day treatment course. Seventeen patients (13 men and 4 women, median age 57, all previously treated with chemotherapy) were treated with 68 courses at 3 dose levels: 800/200, 1,000/200, and 1,000/300 [GEM (mg/m2/week)/ 5-FU (mg/m2/day)]. Two further patients were not fully evaluable for toxicity; one died from a probable pulmonary embolism, and one refused further treatment after developing grade II mucositis and dermatitis after her day 1 to 7 treatment. At the third dose level, 2 of 4 patients developed grade III mucositis; one also developed grade IV neutropenia with fever and grade III thrombocytopenia. Patient accrual then resumed at the second dose level. At this level, 10 patients were treated, with two developing grade III mucositis. One of these patients also developed grade IV dermatitis. No other patient developed grade III or IV side effects. Prophylactic dexamethasone was initiated after 4 of the first 7 patients (including 1 of the not fully evaluable patients) developed dermatitis-grade IV in 1 patient and grade II in the remaining 3 patients. After the steroids were initiated, 4 of the last 11 patients treated developed dermatitis, but grade 1 in all cases. One patient with metastatic gastric cancer achieved a near-complete response of his gastric mass and adrenal metastasis. Minor responses were achieved in a patient with colon carcinoma and a patient with an ethmoid sinus adenoid cystic carcinoma. The MTD and recommended dose for phase II clinical trials of GEM and 5-FU on the above schedule is 1,000 mg/m2 and 200 mg/m2 respectively, with mucositis as the DLT.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Adulto , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , GencitabinaRESUMO
The C-terminal two-thirds segment of integrase derived from the simian immunodeficiency virus has been cloned, expressed in Escherichia coli, and purified to greater than 95% homogeneity. The protein encompasses amino-acid residues 50-293 and contains a F185H substitution to enhance solubility. In dilute solutions at concentrations below 1 mg ml(-1), the enzyme is predominantly dimeric. At the higher concentrations (>10 mg ml(-1)) required to enable crystallization, the enzyme self-associates to form species with molecular weights greater than 200 kDa. Despite the apparent high aggregation in solution, the enzyme crystallizes from a 8%(v/v) polyethylene glycol (molecular weight 6000) solution in a form suitable for X-ray diffraction studies. The resulting single crystals belong to the space group P2(1)2(1)2(1), with unit-cell parameters a = 79.76, b = 99.98, c = 150.2 A, alpha = beta = gamma = 90 degrees and Z = 4. Under X-ray irradiation generated with a rotating-anode generator, the crystals diffract to 2.8 A resolution and allow collection of a native 3 A resolution diffraction data set.
Assuntos
Integrases/química , Vírus da Imunodeficiência Símia/enzimologia , Clonagem Molecular , Cristalização , Dimerização , Escherichia coli , Integrases/genética , Integrases/isolamento & purificação , Mutação , Polietilenoglicóis , Conformação Proteica , Proteínas Recombinantes/isolamento & purificação , Software , Solubilidade , Ultracentrifugação , Difração de Raios XRESUMO
Analytical ultracentrifugation has again become a widely used biomolecular research technique for determining sample purity, characterizing assembly and disassembly mechanisms of biomolecular complexes, determining subunit stoichiometries, detecting and characterizing macromolecular conformational changes, and measuring equilibrium constants and thermodynamic parameters for self- and hetero-associating systems. Concomitant with the availability of modern instrumentation is a strong need for biomedical scientists to become acquainted with the fundamental principles of analytical ultracentrifugation and the new data analysis methodologies that have greatly transformed this technique as it exists today.
RESUMO
Thrombocytopenia has been characterized in six patients infected with human immunodeficiency virus (HIV) with respect to the delivery of viable platelets into the peripheral circulation (peripheral platelet mass turnover), marrow megakaryocyte mass (product of megakaryocyte number and volume), megakaryocyte progenitor cells, circulating levels of endogenous thrombopoietin (TPO) and platelet TPO receptor number, and serum antiplatelet glycoprotein (GP) IIIa49-66 antibody (GPIIIa49-66Ab), an antibody associated with thrombocytopenia in HIV-infected patients. Peripheral platelet counts in these patients averaged 46 +/- 43 x 10(3)/microL (P = . 0001 compared to normal controls of 250 +/- 40x 10(3)/microL), and the mean platelet volume (MPV) was 10.5 +/- 2.0 fL (P > 0.3 compared with normal control of 9.5 +/- 1.7 fL). The mean life span of autologous 111In-platelets was 87 +/- 39 hours (P = .0001 compared with 232 +/- 38 hours in 20 normal controls), and immediate mean recovery of 111In-platelets injected into the systemic circulation was 33% +/- 16% (P = .0001 compared with 65% +/- 5% in 20 normal controls). The resultant mean peripheral platelet mass turnover was 3.8 +/- 1.5 x 10(5) fL/microL/d versus 3.8 +/- 0.4 x 10(5) fL/microL/d in 20 normal controls (P > .5). The mean endogenous TPO level was 596 +/- 471 pg/mL (P = .0001 compared with 95 +/- 6 pg/mL in 98 normal control subjects), and mean platelet TPO receptor number was 461 +/- 259 receptors/platelet (P = .05 compared with 207 +/- 99 receptors/platelet in nine normal controls). Antiplatelet GPIIIa49-66Ab levels in sera were uniformly increased in HIV thrombocytopenic patients (P < .001). In this cohort of thrombocytopenic HIV patients, marrow megakaryocyte number was increased to 30 +/- 15 x 10(6)/kg (P = .02 compared with 11 +/- 2.1 x 10(6)/kg in 20 normal controls), and marrow megakaryocyte volume was 32 +/- 0.9 x 10(3) fL (P = .05 compared with 28 +/- 4.5 x 10(3) fL in normal controls). Marrow megakaryocyte mass was expanded to 93 +/- 47 x 10(10) fL/kg (P = .007 compared with normal control of 31 +/- 5.3 x 10(10) fL/kg). Marrow megakaryocyte progenitor cells averaged 3.3 (range, 0.4 to 7.3) CFU-Meg/1,000 CD34(+) cells compared with 27 (range, 0.1 to 84) CFU-Meg/1,000 CD34(+) cells in seven normal subjects (P = .02). Thus, thrombocytopenia in these HIV patients was caused by a combination of shortening of platelet life span by two thirds and doubling of splenic platelet sequestration, coupled with ineffective delivery of viable platelets to the peripheral blood, despite a threefold TPO-driven expansion in marrow megakaryocyte mass. We postulate that this disparity between circulating platelet product and marrow platelet substrate results from direct impairment in platelet formation by HIV-infected marrow megakaryocytes.
Assuntos
Infecções por HIV/complicações , Proteínas de Neoplasias , Receptores de Citocinas , Trombocitopenia/fisiopatologia , Adulto , Antígenos CD/imunologia , Células da Medula Óssea/citologia , Sobrevivência Celular , Anticorpos Anti-HIV/imunologia , Hematopoese , Humanos , Integrina beta3 , Masculino , Megacariócitos/citologia , Glicoproteínas da Membrana de Plaquetas/imunologia , Proteínas Proto-Oncogênicas/metabolismo , Receptores de Trombopoetina , Trombopoetina/sangueRESUMO
The crystal structure of the NS3 protease of the hepatitis C virus (BK strain) has been determined in the space group P6(3)22 to a resolution of 2.2 A. This protease is bound with a 14-mer peptide representing the central region of the NS4A protein. There are two molecules of the NS3(1-180)-NS4A(21'-34') complex per asymmetric unit. Each displays a familiar chymotrypsin-like fold that includes two beta-barrel domains and four short alpha-helices. The catalytic triad (Ser-139, His-57, and Asp-81) is located in the crevice between the beta-barrel domains. The NS4A peptide forms an almost completely enclosed peptide surface association with the protease. In contrast to the reported H strain complex of NS3 protease-NS4A peptide in a trigonal crystal form (Kim JL et al., 1996, Cell 87:343-355), the N-terminus of the NS3 protease is well-ordered in both molecules in the asymmetric unit of our hexagonal crystal form. The folding of the N-terminal region of the NS3 protease is due to the formation of a three-helix bundle as a result of crystal packing. When compared with the unbound structure (Love RA et al., 1996, Cell 87:331-342), the binding of the NS4A peptide leads to the ordering of the N-terminal 28 residues of the NS3 protease into a beta-strand and an alpha-helix and also causes local rearrangements important for a catalytically favorable conformation at the active site. Our analysis provides experimental support for the proposal that binding of an NS4A-mimicking peptide, which increases catalytic rates, is necessary but not sufficient for formation of a well-ordered, compact and, hence, highly active protease molecule.
Assuntos
Proteínas não Estruturais Virais/química , Sequência de Aminoácidos , Sítios de Ligação/fisiologia , Quimotripsina/química , Cristalografia por Raios X , Hepacivirus/enzimologia , Modelos Moleculares , Dados de Sequência Molecular , Peptídeos/química , Ligação Proteica/fisiologia , Conformação Proteica , Dobramento de Proteína , Estrutura Secundária de Proteína , Proteínas Virais/químicaRESUMO
Body weight of rats placed acutely on a palatable diet is significantly reduced following chronic administration of µ (9%), κ1 (3%) or δ2 (6%) opioid antagonists. Whereas weight loss is comparable in lean Zucker rats (8-11%) following these antagonists, greater weight loss occurs in genetically-obese Zucker rats following chronic µ (10%) and δ2 (7%), relative to κ1 (2%) antagonism. The present study examined whether rats exposed to high-energy diets (6 weeks) that were either high-carbohydrate or high-fat displayed differential weight and intake reductions following chronic (7 days) daily central administration of equimolar doses (5,20,40 nmol) of selective µ(ß-funaltrexamine), κ1 (nor-binaltorphamine) or δ2 (naltrindole isothiocyanate) opioid antagonists. The high-fat diet stimulated significantly greater weight gain (165 g) than the high-carbohydrate diet. Greater magnitudes and potencies of weight loss were noted for the high-fat diet following µ (11.5%, 3.0 nmol), δ2 (8.4%, 0.01 nmol) and κ1 (6.2%, 17.8 nmol) antagonists relative to the high-carbohydrate diet µ: 5.8%, 27.5 nmol; δ2: 1.3%, >1000 nmol; κ1: 2.4%, >1000 nmol). Antagonist-induced weight losses in either dietary group could not be predicted by corresponding intake alterations. These data underscore the importance of dietary history in mediating opioid antagonist effects upon weight, and establishes the µ receptor as the most consistent opioid mediator of weight control.
RESUMO
Ribonuclease L (RNase L) is an endoribonuclease that is activated upon binding of adenosine oligomers linked 2' to 5' to cleave viral and cellular RNAs. We recently proposed a model for activation in which activator A binds to monomer, E, to form EA, which subsequently dimerizes to the active form, E2A2 (Cole, J. L., Carroll, S. S., and Kuo, L. C. (1996) J. Biol. Chem. 271, 3978-3981). Here, we have employed this model to define the equilibrium constants for activator binding (Ka) and dimerization of EA to E2A2 (Kd) by equilibrium analytical ultracentrifugation and fluorescence measurements. Multi-wavelength sedimentation data were globally fit to the model above, yielding values of Ka = 1.69 microM and Kd = 17. 8 nM for 2',5'-linked adenosine trimer. Fluorescent conjugates of 2',5'-linked adenosine trimer with 7-hydroxycoumarin have been prepared. The coumarin emission anisotropy shows a large increases upon binding to RNase L. Analysis of anisotropy titrations yields values of Ka and Kd close to those obtained by sedimentation. The sedimentation parameters for unmodified 2',5'-linked adenosine trimer also agree with those obtained by enzyme kinetic methods (Carroll, S. S., Cole, J. L., Viscount, T., Geib, J., Gehman, J., and Kuo, L. C. (1997) J. Biol. Chem. 272, 19193-19198). Thus, the data presented here clearly define the energetics of RNase L activation and support the minimal activation model.
Assuntos
Nucleotídeos de Adenina/farmacologia , Endorribonucleases/química , Oligorribonucleotídeos/farmacologia , Endorribonucleases/metabolismo , Ativação Enzimática , Polarização de Fluorescência , Humanos , CinéticaRESUMO
Ribonuclease L (RNase L), the 2',5'-oligoadenylate-dependent ribonuclease, is one of the cellular antiviral systems with enhanced activity in the presence of interferon. A reaction scheme has been developed to model the sequence of steps necessary for the activation of RNase L (Cole, J. L., Carroll, S. S., Blue, E. S., Viscount, T., and Kuo, L. C. (1997) J. Biol. Chem. 272, 19187-19192). The model comprises three sequential binding steps: the binding of activator to enzyme monomer, the subsequent dimerization of the activated monomer to form the active enzyme dimer, followed by the binding of substrate prior to catalysis. The model is used to evaluate the activation of RNase L by several synthetic analogs of the native activator. The 5'-phosphate of the activator has been determined to be an important structural determinant for the efficient activation of RNase L, and its loss caused a loss of activator affinity of 2-3 orders of magnitude. The length of activator is not an important determinant of activator potency for the activator analogs examined. The specific activity of the enzyme under conditions of saturation of activator binding and complete dimerization of the activated monomers varies only by about a factor of 3 for the activators examined, indicating that once dimerized in the presence of any of these activators, the enzyme exhibits a similar catalytic activity.
Assuntos
Nucleotídeos de Adenina/farmacologia , Oligorribonucleotídeos/farmacologia , Ribonucleases/metabolismo , Dimerização , Ativação Enzimática , Humanos , Cinética , Ribonucleases/químicaRESUMO
Body weight and food intake are significantly reduced in rats during development of dietary obesity following chronic central administration of mu (beta-funaltrexamine, BFNA), mu1 (naloxonazine), kappa1 (nor-binaltorphamine, NBNI), delta1 ([D-Ala2,Leu5,Cys6]-enkephalin, DALCE) and delta2 (naltrindole isothiocyanate, NTII) opioid receptor subtype antagonists. In contrast, rats made obese by maintainance on a 'cafeteria' diet failed to display weight loss following chronic mu1 receptor antagonism. To test the hypothesis that chronic administration of opioid antagonists are less effective in controlling intake and weight in obese animals, the present study assessed whether chronic, central administration of either BFNA (20 micrograms), naloxonazine (50 micrograms), NBNI (20 micrograms), DALCE (40 micrograms) or NTII (20 micrograms) altered weight and intake in lean and obese Zucker rats over seven days. Body weight was reduced following chronic mu (lean: 42 g; obese: 49 g), mu1 (lean: 71 g; obese: 38 g), kappa1 (lean: 30 g; obese 14 g), delta1 (lean: 43 g; obese: 22 g) or delta2 (lean: 37.5 g; obese: 36 g) antagonism. Overall food intake was reduced following chronic mu (lean: 8.8 g; obese: 16.1 g), mu1 (lean: 12.6 g; obese: 17.0 g), kappa1 (lean: 6.5 g; obese 7.0 g), delta1 (lean: 9.7 g; obese: 11.1 g) or delta2 (lean: 9.4 g; obese: 14.3 g) antagonism. Therefore, both lean and obese Zucker rats display weight loss and reduced intake following chronic central administration of opioid receptor subtype antagonists.
Assuntos
Peso Corporal/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Obesidade/fisiopatologia , Receptores Opioides delta/antagonistas & inibidores , Receptores Opioides kappa/antagonistas & inibidores , Receptores Opioides mu/antagonistas & inibidores , Animais , Depressão Química , Masculino , Ratos , Ratos ZuckerRESUMO
Human cytomegalovirus, a member of the herpesvirus family, encodes a maturational protease required for processing of the assembly protein and virus replication. The protease is synthesized as a precursor protein that undergoes autoproteolytic cleavage to yield a mature, 28-kDa enzyme. It has recently been demonstrated that mature human cytomegalovirus protease is capable of dimerization and that the dimer is the active species [Darke, P. L., Cole, J. L., Waxman, L., Hall, D. L., Sardana, M. K., & Kuo, L. C. (1996) J. Biol. Chem. 271, 7445-7449; Margosiak, S. A., Vanderpool, D. L., Sisson, W., Pinko, C., & Kan, C.-C. (1996) Biochemistry 35, 5300-5307]. Here, analytical equilibrium and velocity sedimentation measurements were used to define the thermodynamics of protease dimerization. Protease dimerization is well described by a homogeneous, reversible mass-action equilibrium. The apparent molecular weight of the protease decreases at higher protein concentrations, and good global fits to sedimentation equilibrium data require a positive value of the second virial coefficient, indicating that the protein exhibits thermodynamic nonideality. The magnitude of the nonideality is higher than expected on the basis of excluded volume and electrostatic effects and is not very sensitive to salt concentration, as would be expected for electrostatic effects. The dimer dissociation constants are in agreement with the values we previously determined by activity measurements and hydrodynamic techniques. Dimerization is enhanced by addition of glycerol or NaCl. The temperature dependence of the dimerization constant indicates that both delta H degree and delta S degree are negative, which is commonly observed in protein self-association reactions.
Assuntos
Citomegalovirus/enzimologia , Endopeptidases/metabolismo , Serina Endopeptidases , Centrifugação , Humanos , Peso MolecularRESUMO
Opioid agonists produce biphasic (decreases then increases) effects upon activity in rats. General opioid antagonists typically suppress activity. Selective opioid antagonists reduce weight and food intake. However, the latter effects cannot fully account for the former effects. To assess the possibility that selective opioid antagonists might decrease weight by increasing activity, the present study examined whether central administration of either mu (beta-funaltrexamine: 20 micrograms), mu1 (naloxonazine: 50 micrograms), delta1 ([D-Ala2,Leu5,Cys6]enkephalin: 40 micrograms), delta2 (naltrindole isothiocyanate: 20 micrograms), or kappa1 (nor-binaltorphamine: 20 micrograms) opioid antagonists altered total, ambulatory, or stereotypic activity. Each of the antagonists significantly reduced total (mu: 18%, mu1: 31%, delta1: 42%, delta2: 37%, kappa1: 31%), ambulatory (mu: 17%, mu1: 27%, delta1: 34%, delta2: 37%, kappa1: 31%), and stereotypic (mu: 19%, mu1: 34%, delta1: 49%, delta2: 37%, kappa1: 31%) activity on the first day. All three activity measures were reduced by delta1 and delta2 antagonism on the second day, whereas mu antagonism reduced total and stereotypic activity on the second day. The activity reductions induced by selective opioid receptor subtype antagonists parallel effects induced by general opioid antagonism, and suggest that antagonist-induced weight loss effects independent of intake reductions are not due to antagonist-induced hyperactivity.
Assuntos
Encefalinas/farmacologia , Locomoção/efeitos dos fármacos , Naloxona/análogos & derivados , Naltrexona/análogos & derivados , Antagonistas de Entorpecentes , Animais , Masculino , Naloxona/farmacologia , Naltrexona/farmacologia , Ratos , Ratos Sprague-DawleyRESUMO
MOR-1 encodes a mu receptor. In an effort to establish the relationship of this cloned opioid receptor with ingestive behavior and analgesia in rats, the present study examined the actions of four antisense oligodeoxynucleotides aimed at exons 1 (AS1), 2 (AS2), 3 (AS3) and 4 (AS4) of the MOR-1 clone, as well as a mismatch antisense sequence (MS1). Rats were administered intracerebroventricular injections (10 micrograms/2 microliters) of each of the oligodeoxynucleotides on days 1, 3 and 5. Body weight and spontaneous food and water intake were monitored daily. In addition, 2-deoxy-D-glucose (2DG)-induced hyperphagia, central Angiotensin II (ANG-II) induced hyperdipsia and central morphine analgesia were examined 24 h following the last antisense injection. AS1, AS2, AS3 and AS4 each significantly reduced body weight (7-17 g), food intake (8-13 g) and water intake (11-23 ml), while the vehicle or MS1 conditions significantly increased weight (9-20 g) and produced smaller reductions (2-4 g) in food intake. None of the AS probes altered the magnitude of either 2DG-induced hyperphagia or ANG-II-induced hyperdipsia. Central morphine analgesia was reduced by pretreatment with AS1 and AS4, but not AS2, AS3 or MS1. The sensitivity of general feeding to all four exons suggest that the receptor responsible for this action is encoded by the MOR-1 clone. The differences between feeding and morphine analgesia raise the possibility that these two actions are mediated through different mu receptor subtypes. Our results also demonstrate the viability of the in vivo antisense technique in modulating opioid-mediated ingestive responses.
Assuntos
Peso Corporal/efeitos dos fármacos , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Éxons , Comportamento Alimentar/efeitos dos fármacos , Oligonucleotídeos Antissenso/farmacologia , Analgésicos Opioides/farmacologia , Angiotensina II/farmacologia , Animais , Clonagem Molecular , Desoxiglucose/farmacologia , Hiperfagia/induzido quimicamente , Injeções Intraventriculares , Masculino , Morfina/farmacologia , Ratos , Ratos Sprague-DawleyRESUMO
Influenza virus utilizes a unique mechanism for initiating the transcription of viral mRNA. The viral transcriptase ribonucleoprotein complex hydrolyzes host cell transcripts containing the cap 1 structure (m7GpppG(2'-OMe)-) to generate a capped primer for viral mRNA transcription. Basic aspects of this viral endonuclease reaction are elucidated in this study through the use of synthetic, radiolabeled RNA substrates and substrate analogs containing the cap 1 structure. Unlike most ribonucleases, this viral endonuclease is shown to catalyze the hydrolysis of the scissile phosphodiester, resulting in 5'-phosphate- and 3'-hydroxyl-containing fragments. Nevertheless, the 2'-OH adjacent to the released ribosyl 3'-OH is shown to be important for catalysis. In addition, while the endonuclease steady-state turnover rate is measured to be 2 h(-1), phosphodiester bond hydrolysis is not rate-limiting. The direct generation of a free 3'-OH and the subsequent slow release of this product are consistent with the viral need for efficient use of the capped primer in subsequent reactions of the influenza transcriptase complex.
Assuntos
Endorribonucleases/metabolismo , Oligorribonucleotídeos/síntese química , Oligorribonucleotídeos/metabolismo , Orthomyxoviridae/enzimologia , RNA Mensageiro/biossíntese , RNA Viral/biossíntese , RNA/metabolismo , Autorradiografia , Sequência de Bases , Primers do DNA , Cinética , Dados de Sequência Molecular , Oligorribonucleotídeos/química , Radioisótopos de Fósforo , RNA/síntese química , Capuzes de RNA/metabolismo , Especificidade por Substrato , Transcrição GênicaRESUMO
The quaternary state of the human cytomegalovirus (hCMV) protease has been analyzed in relation to its catalysis of peptide hydrolysis. Based on results obtained from steady state kinetics, size exclusion chromatography, and velocity sedimentation, the hCMV protease exists in a monomer-dimer equilibrium. Dimerization of the protease is enhanced by the presence of glycerol and high concentrations of enzyme. Isolation of monomeric and dimeric species eluted from a size exclusion column, followed by immediate assay, identifies the dimer as the active species. Activity measurements conducted with a range of enzyme concentrations are also consistent with a kinetic model in which only the dimeric hCMV protease is active. Using this model, the dissociation constant of the protease is 6.6 microM in 10% glycerol and 0.55 microM in 20% glycerol at 30 degrees C and pH 7.5.
Assuntos
Citomegalovirus/enzimologia , Endopeptidases/química , Endopeptidases/metabolismo , Conformação Proteica , Serina Endopeptidases , Sequência de Aminoácidos , Cromatografia em Gel , Endopeptidases/biossíntese , Endopeptidases/isolamento & purificação , Glicerol/farmacologia , Humanos , Cinética , Substâncias Macromoleculares , Dados de Sequência Molecular , Peso Molecular , Oligopeptídeos/síntese química , Oligopeptídeos/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Especificidade por SubstratoRESUMO
Ribonuclease L is an endoribonuclease that is activated by binding of 2',5'-linked oligoadenylates. Activation of ribonuclease L also induces dimerization. Here, we demonstrate using equilibrium sedimentation that dimerization requires the binding of one 5'-monophosphate 2',5'-(adenosine)3 molecule per ribonuclease L monomer. No dimerization was observed in the absence of activator up to a protein concentration of 18 microM, indicating that unliganded enzyme is unable to dimerize or the association is very weak. In parallel with dimerization, enzymatic activity is also maximized at a 1:1 activator: ribonuclease L stoichiometry. The same stoichiometry for dimerization is observed using a nonphosphorylated activator 2'-5'-(adenosine)3. Adenosine triphosphate or RNA oligonucleotide substrates do not induce dimerization. The observed stoichiometry supports a model for ribonuclease L dimerization in which activator binds to monomer, which subsequently dimerizes.